Correlations between in vitro and in vivo data (IVIVC) are often used during pharmaceutical development in order to reduce development time and optimize the. This presentation gives a bird’s eye view on Dissolution in context with IVIVC. It discusses various levels of Correlations currently in practice. Invitro Invivo study & their correlation shortens the drug development period, economizes the resources and leads to improved product quality. Increased activity.

Author: Shakam Tozilkree
Country: Algeria
Language: English (Spanish)
Genre: Literature
Published (Last): 26 February 2011
Pages: 471
PDF File Size: 12.25 Mb
ePub File Size: 15.26 Mb
ISBN: 255-1-90652-684-5
Downloads: 28758
Price: Free* [*Free Regsitration Required]
Uploader: Karr

Dissolution in jejunum compartment a and addition of two additional time points b. At this stage based on a greater understanding and appreciation of defined formulation and its characteristics, a prospective IVIVC is established through a well defined prospective IVIVC study [ 185 ]. The purpose of the invitro dissolution studies in the early stage of drug development is to select the optimum formulation, evaluate the active ingredient and excipients, and assess any minor changes for drug products.

In vitro – in vivo correlation was described by both linear and nonlinear polynomial relationship 3. The key procedure here was a deconvolution of a PK profile into the cumulative curve describing fraction absorbed in vivo. However, the difficulty arises in the variation to be allowed around each time point [ 37 ]. In vivo absorption of atorvastatin is believed to start only in small intestine and thus a deconvolution of plasmatic profile would yield a fraction of drug absorbed only from small intestine.

In vitro – in vivo correlation: from theory to applications.

These so called physiologically based pharmacokinetic PBPK models are capable of translating in vitro results into in vivo predictions. Golem Apparatus The instrument is a computer controlled artificial digestive tract, designed for dynamic dissolution testing of oral dosage forms and consisting of four compartments: Biopharmaceutics Classification System BCS is a fundamental guideline for determining the conditions under which in-vitro, in-vivo correlations are expected [ 25 ].

Retrieved from ” https: Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms. This is the weakest level of correlation as partial relationship between absorption and dissolution is established since it does not reflect the complete shape of plasma drug concentration time curve, which is the critical factor that defines the performance of a drug product.

Since in the presented case, bioassay protocol did not include such atorvastatin administration, an approximation of i. When there is no IVIVC, the tolerance limits may be derived from the spread of in vitro dissolution data of batches with demonstrated acceptable in vivo performance biobatch or by demonstrating bioequivalence between batches at the proposed upper and lower limit of the dissolution range the so called side batch concept. Scale up post approval changes Time and cost saving during the product development.


The in vitro results are then related to in vivo drug plasma concentration profiles see danazol example below. But primarily it is recommended to start with the basket or paddle method prior to using the others [ 26 ].

It is also used as a tool for developing the in-vitro dissolution specification.

Having an established IVIVC can help avoid bioequivalence studies by using the dissolution profile from the changed formulation, and subsequently predicting the in vivo concentration-time profile [ 2441 ].

IVIVC can be developed and applied to parenteral dosage forms, such as controlled-release particulate systems, depot system, implants, etc, that are either injected or implanted. The classification is based on the drug dissolution and absorption model, which identifies the key parameters controlling drug absorption as a set of dimensionless numbers: Prediction errors are estimated for C max and AUC to determine the validity of the correlation.

Ann Jose ankara escort. This assumed model can be the subject of revision as prototype formulations are developed and characterized in vivo, with the results often leading to a further cycle of prototype formulation and In vivo characterization.

Therefore, external predictability and validation were evaluated when one formulation was characterized by medium rate release kinetics, used as testing formulation, and two other formulations were used for model building. Multiple point level C correlation may be used to justify a biowaivers provided that the correlation has been established over the entire dissolution profile with one or more pharmacokinetic parameters of interest. As a result the modeling focuses on the ability to predict measured quantities not indirectly calculated quantities such as the cumulative amount absorbed.

Modified-release dosage forms typically require dissolution testing over multiple time points, and IVIVC plays an important role in setting these specifications [ 2439 ]. Nowadays computer models are often used to link in vitro results with in vivo outcomes.

In vitro – in vivo correlation: from theory to applications.

This class of drugs present significant problems for effective oral delivery. This level refers to the relationship between one or more pharmacokinetic parameters of interest C maxAUC, or any other suitable parameters and amount of drug dissolved at several time point of dissolution profile. External predictability evaluation is not necessary unless the drug is a narrow therapeutic index, or only two release rates were used to develop the IVIVC, or, if the internal predictability criteria are not met i.

The changes may range from minor changes that are not significant to alter product performance to major ones where an IVIVC is not sufficient to justify the change for regulatory decision [ 424 ]. The process of setting dissolution specifications in the presence of an IVIVC starts by obtaining the reference pivotal clinical batch dissolution profile. Prediction of Sortis06 profile with model built on batch80 and Lipitor.


Its main advantage is that the complex functions are based on simple technical solutions which make jviv apparatus user friendly and easy to modify, and at the same time significantly less expensive than the alternatives. Based on the IVIVC model, the predicted fraction of the drug absorbed is calculated from the observed fraction of the drug dissolved.

By this phase of the development process, a defined formulation that meets the In ivv targets has been achieved.

Any well designed and scientifically sound approach would be acceptable for establishment of an IVIVC. For the IVIVC development, the dissolution profiles of at least 12 individual dosage units from each lot should be determined.

All formulations with the crystal ATV also contained CaCO 3 as a buffering agent used to raise the gastric pH and correlahion facilitate very early dissolution of ATV, which is a weak acid almost insoluble in pH below 4.

Use of sinkers may be avoided as these often alter the dissolution characteristics of the test products.

The same principles of IVIVC used for oral extended release products may be applied for non-oral products such as parenteral correlxtion formulations and novel drug delivery systems as well. The biorelevant conditions and observation of succeeding dissolution processes in separate compartments provided comprehensive information on the dissolution behavior expected in vivo.

BioMed Research International

From the correlation-development view, however, the basis for direct correlation was purely empirical. Then, the pharmacokinetic parameters are estimated using a nonlinear regression tool or obtained from literatures reported previously. In context of understanding the applications of IVIVR throughout the product development cycle, it is useful to become familiar with the following terms as they relate corrrlation a typical product development cycle for oral extended-release product [ 5 ].

Scale-up and post approval changes [ 2 ]. The latter may involve normalization with a common reference treatment. The defined formulation that meets the in vivo specification is employed for Stage 2. Cotrelation most important origin of the variability seems to be the gut and liver metabolism of the drug [ 16 ].

An example of internal predictability is presented in Figure The BCS thus enables manufacturers to reduce the cost of approving scale-up and post approval changes to certain oral drug products without compromising public safety interests [ 33 ].